The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor

Yashini Govender, Chanel Avenant, Nicolette J D Verhoog, Roslyn M Ray, Nicholas J Grantham, Donita Africander, Janet P Hapgood, Yashini Govender, Chanel Avenant, Nicolette J D Verhoog, Roslyn M Ray, Nicholas J Grantham, Donita Africander, Janet P Hapgood

Abstract

Clinical studies suggest that the injectable contraceptive medroxyprogesterone acetate (MPA) increases susceptibility to infections such as HIV-1, unlike the injectable contraceptive norethisterone enanthate (NET-EN). We investigated the differential effects, molecular mechanism of action and steroid receptor involvement in gene expression by MPA as compared to NET and progesterone (P4) in the End1/E6E7 cell line model for the endocervical epithelium, a key point of entry for pathogens in the female genital mucosa. MPA, unlike NET-acetate (NET-A) and P4, increases mRNA expression of the anti-inflammatory GILZ and IκBα genes. Similarly, MPA unlike NET-A, decreases mRNA expression of the pro-inflammatory IL-6, IL-8 and RANTES genes, and IL-6 and IL-8 protein levels. The predominant steroid receptor expressed in the End1/E6E7 and primary endocervical epithelial cells is the glucocorticoid receptor (GR), and GR knockdown experiments show that the anti-inflammatory effects of MPA are mediated by the GR. Chromatin-immunoprecipitation results suggest that MPA, unlike NET-A and P4, represses pro-inflammatory cytokine gene expression in cervical epithelial cells via a mechanism involving recruitment of the GR to cytokine gene promoters, like the GR agonist dexamethasone. This is at least in part consistent with direct effects on transcription, without a requirement for new protein synthesis. Dose response analysis shows that MPA has a potency of ∼ 24 nM for transactivation of the anti-inflammatory GILZ gene and ∼ 4-20 nM for repression of the pro-inflammatory genes, suggesting that these effects are likely to be relevant at injectable contraceptive doses of MPA. These findings suggest that in the context of the genital mucosa, these GR-mediated glucocorticoid-like effects of MPA in cervical epithelial cells are likely to play a critical role in discriminating between the effects on inflammation caused by different progestins and P4 and hence susceptibility to genital infections, given the predominant expression of the GR in primary endocervical epithelial cells.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. MPA, but not NET-A or…
Figure 1. MPA, but not NET-A or P4, acts like a partial GR agonist for upregulation of anti-inflammatory mRNAs.
(A and B) End1/E6E7 cells were treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). (C and D) HeLa cells were treated for 24 hrs with 100 nM DEX, 1 µM MPA, 10 µM P4, 10 µM NET-A or vehicle (ethanol) (CTRL). Thereafter the cells were harvested; total RNA was isolated and reverse-transcribed. Relative GILZ and IκBα gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expression was normalized to basal activity (CTRL) in order to obtain relative fold expression. Graphs represent pooled results of at least three independent experiments and are plotted as mean ±SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance is denoted by *, ** or *** to indicate P<0.05, P<0.001 or P<0.0001, respectively.
Figure 2. MPA, but not NET-A, acts…
Figure 2. MPA, but not NET-A, acts like a full/partial GR agonist for repression of pro-inflammatory mRNAs.
(A–C) End1/E6E7 cells were treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). (D–H) HeLa cells were treated for 24 hrs (D–F) or 4 hrs (G–H) with 100 nM DEX, 1 µM MPA, 10 µM P4, 10 µM NET-A or vehicle (ethanol) (CTRL). Thereafter the cells were harvested, total RNA was isolated and reverse-transcribed. Relative IL-6, IL-8 and RANTES gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expression was normalized to basal activity (CTRL) in order to obtain relative fold expression. Graphs represent pooled results of at least three independent experiments and are plotted as mean ± SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance is denoted by *, ** or *** to indicate P<0.05, P<0.001 or P<0.0001, respectively.
Figure 3. MPA-mediated regulation of inflammatory gene…
Figure 3. MPA-mediated regulation of inflammatory gene mRNA levels is dose- and time-dependent.
End1/E6E7 cells were treated with increasing amounts (1 nM, 10 nM, 100 nM and 1 µM) of DEX, MPA, P4 or NET-A, or vehicle (ethanol) (CTRL) for 4 and 24 hrs, respectively. Thereafter, the cells were harvested, total RNA was isolated and reverse-transcribed. Relative (A, B) GILZ, (C, D) IL-6, (E, F) IL-8 and (G, H) RANTES gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative GILZ gene expression was normalized to 1 µM DEX set to 100% in order to obtain % partial agonist activity. Relative IL-6, IL-8 and RANTES expression was normalized to basal activity (CTRL) set to 100 in order to obtain % repression. For IL-6 and RANTES mRNA, statistically significant repression with MPA relative to control was found at 10 nM, 100 nM and 1 µM. The 1 µM data point for P4 on IL-8 4 hrs (E) is 231% and is not displayed due to the y-axis scale. Graphs represent pooled results of at least three independent experiments and are plotted as mean ± SEM.
Figure 4. End1/E6E7 and HeLa cells only…
Figure 4. End1/E6E7 and HeLa cells only express detectable GR protein.
(A and B) (A) HeLa and End1/E6E7 cells were harvested, total RNA was isolated and reverse-transcribed. Steroid receptor (SR) gene expression was measured by real time qRT-PCR. SR expression vectors (pcDNA3-hGR, pMT-PR-B, pSV-hAR, pRS-hMR and pSG5-hER) served as positive controls (+CTRL) for the GR, PR-B, MR and ER, respectively. COS-1 cells transiently transfected with pcDNA3 (empty vector) served as negative control (−CTRL). (B) Whole cell lysates were prepared from the HeLa and End1/E6E7 cell lines. Equal volumes of lysate were analysed by Western blotting with antibodies against specific SRs and GAPDH as loading control. (C and D) SR agonist screen indicates that in the cervical cells the GR, but not the MR or AR repress IL-6 and IL-8 in the presence of receptor-specific agonist. HeLa cells were treated with 100 nM DEX, 100 nM mibolerone (MIB), 10 nM aldosterone (ALD) or vehicle (ethanol) (CTRL) for 4 hrs. Total RNA was isolated and reverse-transcribed. Relative (C) IL-6 and (D) IL-8 gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to obtain fold expression. The primers and antibody used to investigate PR levels are capable of detecting both PR-A and PR-B isoforms, however the positive protein control shown is specific for PR-B isoform only. Graphs represent pooled results of at least three independent experiments and are plotted as mean ± SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance is denoted by * to indicate P<0.001.
Figure 5. Only GR protein is detected…
Figure 5. Only GR protein is detected in primary cervical epithelial cells (VEN-100).
(A) Upon arrival the VEN-100 cells were rested overnight before being washed once with PBS and harvested with TRIzol®. Total RNA was isolated and 500 ng RNA was reverse-transcribed. Steroid receptor gene expression was measured by qRT-PCR with receptor-specific primers, followed by gel electrophoresis to confirm the PCR products. (B) VEN-100 cells were rested overnight before harvesting in 2X SDS sample buffer. COS-1 cells were transiently transfected with 1 µg/well pcDNA3 (empty vector) which served as negative control (−CTRL) or with 1 µg/well steroid receptor expression vectors (GR, PR-B, AR, MR and ERα) which served as positive controls (+CTRL). Twenty fourhrs later, the COS-1 cells were washed once and lysed with 2X SDS sample buffer. Equal volumes of cell lysate (VEN-100 and COS-1 ctrls) were analysed by Western blotting with antibodies specific for the GR and Flotillin-1 (loading control), respectively.
Figure 6. MPA- and DEX-mediated upregulation of…
Figure 6. MPA- and DEX-mediated upregulation of anti-inflammatory mRNAs is mediated via the GR.
End1/E6E7 cells were transfected with 10 nM GR or NSC siRNA (A–D) and then treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A, NET or vehicle (ethanol) (CTRL). For verification of GR knockdown a representative blot is shown in (A). (B) Western blots of at least three independent experiments were quantified to determine the relative GR protein expression and is plotted as mean ± SEM. Total RNA was isolated and reverse-transcribed. Relative (C) GILZ and (D) IκBα gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to obtain relative fold expression. Graphs in (C) and (D) represent pooled results of at least three independent experiments and are plotted as mean ± SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with either a Dunnett post-test, followed by a student’s t-test to compare specific conditions to each other. Statistical significance is denoted by * or *** to indicate P<0.05 or P<0.0001, respectively.
Figure 7. MPA- and DEX-mediated repression of…
Figure 7. MPA- and DEX-mediated repression of pro-inflammatory cytokine gene mRNA is mediated via the GR.
End1/E6E7 cells were transfected with 10 nM GR or NSC siRNA (A–F) and then treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). Total RNA was isolated and reverse-transcribed. Relative (A) IL-6 (C) IL-8 and (E) RANTES gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to obtain fold expression. The corresponding cytokine protein levels for (B) IL-6 and (D) IL-8 were determined by Luminex of supernatants collected prior to cell harvest. Graphs represent pooled results of at least three independent experiments and are plotted as mean ± SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with a Dunnett post-test followed by a student’s t-test to compare specific conditions to each other. Statistical significance is denoted by * or ** to indicate P<0.05 or P<0.001, respectively.
Figure 8. The GR at least in…
Figure 8. The GR at least in part directly regulates mRNA levels of the inflammatory genes.
End1/E6E7 cells were pretreated with 1 µg/ml cycloheximide (CHX) then treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL), in the absence or presence of CHX. Total RNA was isolated and reverse-transcribed. Relative (A) GILZ (B) IκBα, (C) RANTES, (D) IL-6 and (E) IL-8 gene expressions was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to obtain relative fold expression. Graphs represent pooled results of at least three independent experiments and are plotted as mean ± SEM. To verify that the CHX inhibited de novo protein synthesis, End1/E6E7 cells were pretreated with CHX then treated with 100 nM DEX or vehicle (ethanol) (CTRL) for 24 hrs. (F) Cells were harvested and equal volumes of lysate were analysed by Western blotting with an antibody specific for IκBα and a GAPDH specific antibody as loading control. (G) Western blots of four independent experiments were quantified to determine the relative GR protein expression. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with a Dunnett post-test followed by a student’s t-test to compare specific conditions to each other. Statistical significance is denoted by *, ** or *** to indicate P<0.05, P<0.001 or P<0.0001, respectively.
Figure 9. DEX and MPA recruit GR…
Figure 9. DEX and MPA recruit GR to the IL-6 and IL-8 cytokine gene promoters.
HeLa cells were serum starved for 2-A or vehicle (ethanol) (CTRL). ChIP was carried out using an anti-GR antibody to immunoprecipitate endogenous GR and an anti-IgG antibody as a negative control. Real-time qRT-PCR was performed on input and immunoprecipitated DNA with primers specific for endogenous (A) GILZ, (B) IL-6 and (C) IL-8 promoters. GR recruitment was measured relative to input. Graphs represent pooled results of at least three independent experiments and are plotted as mean ± SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance is denoted by * or *** to indicate P<0.05 or P<0.0001, respectively.

References

    1. Kaushic C, Ferreira VH, Kafka JK, Nazli A (2010) HIV infection in the female genital tract: discrete influence of the local mucosal microenvironment. Am J Reprod Immunol 63: 566–575.
    1. Kaushic C (2011) HIV-1 infection in the female reproductive tract: role of interactions between HIV-1 and genital epithelial cells. Am J Reprod Immunol 65: 253–260.
    1. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L (2005) Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 206: 306–335.
    1. Barclay C, Brennand J, Kelly R, Calder A (1993) Interleukin-8 production by the human cervix. Am J Obs Gynecol 169: 625–632.
    1. Fichorova RN, Anderson DJ (1999) Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod 60: 508–514.
    1. Woodworth CD, Simpson S (1993) Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines. Am J Pathol 142: 1544–1555.
    1. Fichorova RN, Desai PJ, Gibson III C, Genco CA (2001) Distinct Proinflammatory Host Responses to Neisseria gonorrhoeae Infection in Immortalized Human Cervical and Vaginal Epithelial Cells Distinct Proinflammatory Host Responses to Neisseria gonorrhoeae Infection in Immortalized Human Cervical and Vaginal Ep. Infect Immun 69: 5840–5848.
    1. Rodriguez-Garcia M, Patel MV, Wira CR (2013) Innate and adaptive anti-HIV immune responses in the female reproductive tract. J Reprod Immunol 97: 74–84.
    1. Brabin L (2002) Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression. AIDS Patient Care STDS 16: 211–221.
    1. MacDonald EM, Savoy A, Gillgrass A, Fernandez S, Smieja M, et al. (2007) Susceptibility of human female primary genital epithelial cells to herpes simplex virus, type-2 and the effect of TLR3 ligand and sex hormones on infection. Biol Reprod 77: 1049–1059.
    1. Hel Z, Stringer E, Mestecky J (2010) Sex Steroid Hormones, Hormonal Contraception, and the Immunobiology of Human Immunodeficiency Virus-1 Infection. Endocr Rev 31: 79–97.
    1. Gillgrass AE, Ashkar AA, Rosenthal KL, Kaushic C (2003) Prolonged Exposure to Progesterone Prevents Induction of Protective Mucosal Responses following Intravaginal Immunization with Attenuated Herpes Simplex Virus Type 2. J Virol 77: 9845–9851.
    1. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL (2003) Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection. J Virol 77: 4558–4565.
    1. MacLean R (2005) Injectable use may increase women’s odds of getting chlamydia or gonorrhea. Int Fam Plan Perspect 31: 45–46.
    1. Morrison CS, Bright P, Wong EL, Kwok C, Yacobson I, et al. (2004) Hormonal Contraceptive Use, Cervical Ectopy, and the Acquisition of Cervical Infections. Sex Transm Dis 31: 561–567.
    1. Trunova N, Tsai L, Tung S, Schneider E, Harouse J, et al. (2006) Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology 352: 169–177.
    1. Parr M, Kepple L, McDermott M, Drew M, Bozzola J, et al. (1994) A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 70: 369–380.
    1. WHO website. Hormonal Contraception and HIV: Technical Statment. Available: . Accessed 2014 April 29.
    1. fhi 360 website. Expanding access to injectable contraception. Available: . Accessed 2014 April 29.
    1. Smit JA, Beksinska ME (2013) Hormonal contraceptive continuation and switching in South Africa: Implications for evaluating the association of injectable hormonal contraceptive use and HIV. J Acquir Immune Defic Syndr 62: 363–365.
    1. Blish CA, Baeten JM (2011) Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol 65: 302–307.
    1. Gray RH (2012) Correspondence Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect Dis 12: 507–508.
    1. Heffron R, Donnell D, Rees H, Celum C, Mugo N, et al. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 12: 19–26.
    1. Morrison CS, Nanda K (2012) Hormonal contraception and HIV: an unanswered question. Lancet Infect Dis 12: 2–3.
    1. Morrison CS, Chen P, Kwok C, Richardson BA, Chipato T, et al. (2010) Hormonal Contraception and HIV Acquisition: Reanalysis using Marginal Structural Modeling. AIDS 24: 1778–1781.
    1. Morrison CS, Skoler-Karpoff S, Kwok C, Chen P-L, van de Wijgert J, et al. (2012) Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS 26: 497–504.
    1. Polis CB, Curtis KM (2013) Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 13: 797–808.
    1. McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, et al. (2013) Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 27: 1001–1009.
    1. Wand H, Ramjee G (2012) The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS 26: 375–380.
    1. USAID website. Technical Brief: Hormonal Contraception and HIV. Available: . Accessed 2014 April 29.
    1. Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, et al. (2000) Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis 181: 58–63.
    1. Wang CC, Mcclelland RS, Overbaugh J, Reilly M, Devange D, et al. (2004) The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS 18: 205–209.
    1. Lavreys L, Baeten J, Martin Jr H, Overbaugh J, Mandaliya K, et al. (2004) Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS 18: 695–697.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168–1174.
    1. Gouws E, Stanecki KA, Lyerla R, Ghys PD (2008) The epidemiology of HIV infection among young people aged 15–24 years in southern Africa. AIDS 22: S5–S16.
    1. Hapgood JP, Koubovec D, Louw A, Africander D (2004) Not all progestins are the same: implications for usage. Trends Pharmacol Sci 25: 554–557.
    1. Africander D, Verhoog N, Hapgood JP (2011) Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 76: 636–652.
    1. Stanczyk FZ, Hapgood JP, Winer S, Mishell Jr DR (2013) Progestogens Used in Postmenopausal Hormone Therapy: Differences in Their Pharmacological Properties, Intracellular Actions, and Clinical Effects. Endocr Rev 34: 171–208.
    1. Bray J, Jelinsky S, Ghatge R, Bray J, Tunkey C, et al. (2005) Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol 97: 328–341.
    1. Sitruk-Ware R (2004) Pharmacological profile of progestins. Maturitas 47: 277–283.
    1. Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP (2005) Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol 242: 23–32.
    1. Stanczyk FZ, Roy S (1990) Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 42: 67–96.
    1. Africander D, Louw R, Hapgood JP (2013) Investigating the anti-mineralocorticoid properties of synthetic progestins used in hormone therapy. Biochem Biophys Res Commun 433: 305–310.
    1. Ronacher K, Hadley K, Avenant C, Stubsrud E, Simons SS, et al. (2009) Ligand-selective transactivation and transrepression via the glucocorticoid receptor: Role of cofactor interaction. Mol Cell Endocrinol 299: 219–231.
    1. Kadmiel M, Cidlowski JA (2013) Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 34: 518–530.
    1. Koubovec D, Vanden Berghe W, Vermeulen L, Haegeman G, Hapgood JP (2004) Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells. Mol Cell Endocrinol 221: 75–85.
    1. Bamberger CM, Else T, Bamberger A, Beil FU, Schulte HM (1999) Dissociative Glucocorticoid Activity of Medroxyprogesterone Acetate in Normal Human Lymphocytes. J Clin Endocrinol Metab 84: 4055–4061.
    1. Hapgood JP (2013) Immunosuppressive biological mechanisms support reassessment of use of the injectable contraceptive medroxyprogesterone acetate. Endocrinology 154: 985–988.
    1. Huijbregts RPH, Helton ES, Michel KG, Sabbaj S, Richter HE, et al. (2013) Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology 154: 1282–1295.
    1. Fichorova RN, Rheinwald JG, Anderson D (1997) Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod 57: 847–855.
    1. Cairns C, Cairns W, Okret S (1993) Inhibition of Gene Expression by Steroid Hormone Receptors Via a Negative Glucocorticoid Response Element: Evidence for the Involvement of DNA-Binding and Agonistic Effects of the Antiglucocorticoid/Antiprogestin RU486. DNA Cell Biol 12: 695–702.
    1. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, et al. (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237: 268.
    1. Brinkmann AO, Faber P, van Rooij HC, Kuiper GGJ, Ris C, et al. (1989) The human androgen receptor: Domain structure, genomic organization and regulation of expression. J Steroid Biochem 34: 307–310.
    1. Flouriot G, Brand H, Denger S, Metivier È, Kos M, et al. (2000) Identification of a new isoform of the human estrogen receptor-alpha (hER- a) that is encoded by distinct transcripts and that is able to repress hER- a activation function 1. EMBO J 19: 468–470.
    1. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: 2002–2007.
    1. Verhoog N, Du Toit A, Avenant C, Hapgood JP (2011) Glucocorticoid-independent Repression of TNFa-stimulated IL-6 Expression by the Glucocorticoid Receptor: A potential Mechanism For the Protection Againsts an Excessive Inflammatory Response. J Biol Chem 286: 19297–19310.
    1. Ma H, Shang Y, Lee D, Stallcup M (2003) Study of nuclear receptor-induced transcription complex assembly and histone modification by chromatin immunoprecipitation assays. Methods Enzym 364: 284–296.
    1. Mosmann T (1983) Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and cytotoxicity assays. J Immunol Methods 12: 16.
    1. Ayroldi E, Riccardi C (2009) Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB 23: 3649–3658.
    1. Commins SP, Borish L, Steinke JW (2010) Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol 125: S53–72.
    1. Hermoso MA, Cidlowski JA (2003) Putting the brake on inflammatory responses: the role of glucocorticoids. IUBMB Life 55: 497–504.
    1. Muzikar KA, Nickols NG, Dervan PB (2009) Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression. Proc Natl Acad Sci U S A 106: 16598–16603.
    1. McKay LI, Cidlowski JA (1999) Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20: 435–459.
    1. De Bosscher K, Van Craenenbroeck K, Meijer OC, Haegeman G (2008) Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. Eur J Pharmacol 583: 290–302.
    1. Avenant C, Kotitschke A, Hapgood JP (2010) Glucocorticoid Receptor Phosphorylation Modulates Transcription Efficacy through GRIP-1 Recruitment. Biochemistry 49: 972–985.
    1. King EM, Chivers JE, Rider CF, Minnich A, Giembycz MA, et al. (2013) Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms. PLoS One 8: e53936.
    1. Hadley KE, Louw A, Hapgood JP (2011) Differential nuclear localisation and promoter occupancy play a role in glucocorticoid receptor ligand-specific transcriptional responses. Steroids 76: 1176–1184.
    1. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by Glucocorticoids: Inhibition of NF-kB Activity Through Induction of IkB. Science 270: 286–290.
    1. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin Jr AS (1995) Role of Transcriptional Activation of IkBa in Mediation of Immunosuppression by Glucocorticoids. Science 270: 283–286.
    1. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, et al. (1997) I κ B α -independent downregulation of NF- κ B activity by glucocorticoid receptor. EMBO J 16: 4698–4707.
    1. Newton R, Hart LA, Stevens DA, Bergmann M, Donnelly LE, et al. (1998) Effect of dexamethasone on interleukin-1 β - (IL-1 β) -induced nuclear factor- κ B (NF- κ B) and κ B-dependent transcription in epithelial cells. Eur J Biochem 254: 81–89.
    1. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ (1999) Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF- k B and lack of I- k B involvement. Br J Pharmacol 127: 1003–1011.
    1. Cvoro A, Yuan C, Paruthiyil S, Miller OH, Yamamoto KR, et al. (2011) Cross Talk between Glucocorticoid and Estrogen Receptors Occurs at a Subset of Proinflammatory Genes. J Immunol. 186 (7): 4354–4360.
    1. Tomasicchio M, Avenant C, Du Toit A, Ray RM, Hapgood JP (2013) The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor. PLoS One 8: e62895.
    1. Elovitz M, Wang Z (2004) Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise. Am J Obstet Gynecol 190: 693–701.
    1. Africander D, Louw R, Verhoog N, Noeth D, Hapgood JP (2011) Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception. 84 (4): 423–435.
    1. Pudney J, Quayle AJ, Anderson DJ (2005) Immunological Microenvironments in the Human Vagina and Cervix: Mediators of Cellular Immunity Are Concentrated in the Cervical Transformation Zone. Biol Reprod 73: 1253–1263.
    1. Hapgood JP, Ray RM, Govender Y, Avenant C, Tomasicchio M (2014) Differential glucocorticoid receptor-mediated effects on immunomodulatory gene expression by progestin contraceptives: implications for HIV-1 pathogenesis. Am J Reprod Immunol. doi:.
    1. Al-Hendy A, Salama SA (2006) Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril 86: 686–693.
    1. Vladic-Stjernholm Y, Vladic T, Blesson CS, Ekman-Ordeberg G, Sahlin L (2009) Prostaglandin treatment is associated with a withdrawal of progesterone and androgen at the receptor level in the uterine cervix. Reprod Biol Endocrinol 7: 116.
    1. Hapgood JP, Africander D, Louw R, Ray RM, Rohwer JM (2013) Potency of progestogens used in hormonal therapy: Toward understanding differential actions. J Steroid Biochem Mol Biol: 1–9.
    1. Kirton K, Cornette JC (1974) Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera). Contraception 10: 39–45.
    1. Fotherby K (1983) Variability of pharmacokinetic parameters for contraceptive steroids. Steroid Biochem 19: 817–820.
    1. Janeway Jr CA, Travers P, Walport M (2012) Immunobiology. 8th Editio. Murphy K, editor New York: Garland Science.
    1. Lee B, Montaner LJ (1999) Chemokine immunobiology in HIV-1 pathogenesis. J Leukoc Biol 65: 552–565.
    1. Coleman JS, Hitti J, Bukusi EA, Mwachari C, Muliro A, et al. (2007) Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS 21: 1569–1578.
    1. Sha BE, Zariffard MR, Wang QJ, Chen HY, Bremer J, et al. (2005) Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Myco- plasma hominis. J Infect Dis 191: 25–32.
    1. Morrison C, Fichorova R, Mauck C, Chen P, Kwok C, et al. (2014) Cervical Inflammation and Immunity Associated with Hormonal Contraception, Pregnancy and HIV-1 Seroconversion. JAIDS. doi:.

Source: PubMed

3
Subskrybuj